Genovate Biotechnology, a Taiwanese drug company, has begun construction of a China insulin manufacturing facility in Changzhou Industrial Park, whose total investment may reach $1 billion. The company hopes to become China's largest supplier of insulin, supplanting the three international pharmas that currently control the market. Phase 1 of the project, which got underway this week, is a relatively modest $55 million facility that will house a one-ton fermentation production line, and is expected to be completed in 2018.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
